Online inquiry

IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15072MR)

This product GTTS-WQ15072MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Glioblastoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15072MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12426MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ4166MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ15872MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ6486MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ238MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ9045MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ8636MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ10570MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY­3074828
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW